{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:34:27Z","timestamp":1792316067901,"version":"4.4.0"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T00:00:00Z","timestamp":1484784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We retrospectively studied 340 fit patients with multiple myeloma (MM) who underwent autologous stem cell transplantation (ASCT). We hypothesized that progression\u2010free survival (PFS) of older patients was non\u2010inferior to that of younger patients after ASCT. Our null hypothesis was that the PFS hazard ratio (HR) for a 5\u2010year increase in age was \u22651.05; the alternative (non\u2010inferiority) hypothesis was that the HR was \u22641. The observed HR was 0.94 (95% confidence interval [CI] 0.86\u20101.03); since the CI upper bound was &lt;1.05, we reject the null hypothesis and conclude that PFS in older patients was at least as good as in younger patients. We cannot reject an analogous null hypothesis for overall survival (HR 1.06 [95% CI 0.94\u20101.19]), since the CI upper bound &gt;1.05. Toxicity was similar across ages and transplant\u2010related mortality was minimal. 28% of subjects &lt;65 versus 45% of those \u226565 received maintenance therapy. In summary, ASCT prolongs PFS equally well in older vs. younger adults. Although we cannot exclude maintenance as a confounder, these data support ASCT for fit seniors with MM.<\/jats:p>","DOI":"10.1002\/hon.2379","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T07:13:36Z","timestamp":1484896416000},"page":"752-759","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of high\u2010dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma"],"prefix":"10.1002","volume":"35","author":[{"given":"Li\u2010Wen","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Duke University Medical Center  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendi","family":"Bacon","sequence":"additional","affiliation":[{"name":"Division of Hematological Malignancies and Cellular Therapy Duke Cancer Institute  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Cirrincione","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics Duke University Medical Center  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bercedis","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics Duke University Medical Center  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwynn","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Duke University Medical Center  Durham NC USA"},{"name":"Division of Hematological Malignancies and Cellular Therapy Duke Cancer Institute  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rizzieri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Duke University Medical Center  Durham NC USA"},{"name":"Division of Hematological Malignancies and Cellular Therapy Duke Cancer Institute  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith M.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Duke University Medical Center  Durham NC USA"},{"name":"Division of Hematological Malignancies and Cellular Therapy Duke Cancer Institute  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Corbet","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Duke University Medical Center  Durham NC USA"},{"name":"Division of Hematological Malignancies and Cellular Therapy Duke Cancer Institute  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Duke University Medical Center  Durham NC USA"},{"name":"Division of Hematological Malignancies and Cellular Therapy Duke Cancer Institute  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Duke University Medical Center  Durham NC USA"},{"name":"Division of Hematological Malignancies and Cellular Therapy Duke Cancer Institute  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Duke University Medical Center  Durham NC USA"},{"name":"Division of Hematological Malignancies and Cellular Therapy Duke Cancer Institute  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-1573","authenticated-orcid":false,"given":"Sascha A.","family":"Tuchman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Duke University Medical Center  Durham NC USA"},{"name":"Division of Hematological Malignancies and Cellular Therapy Duke Cancer Institute  Durham NC USA"},{"name":"Division of Hematology and Oncology University of North Carolina \u2013 Chapel Hill Comprehensive Cancer Center  Chapel Hill NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,19]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00389-7"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402888"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.255"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.07.013"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21191"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt509"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.606942"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647636"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2012-0209-OA"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.099358"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0167"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26646"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7625"},{"issue":"15","key":"e_1_2_5_23_1","article-title":"Geriatric assessment (GA) and eligibility for autologous stem cell transplant (ASCT) in older adults with newly diagnosed multiple myeloma (MM)","volume":"33","author":"Wildes TM","year":"2015","journal-title":"ASCO Meeting Abstracts"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2379","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T16:57:07Z","timestamp":1695488227000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,19]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1002\/hon.2379"],"URL":"https:\/\/doi.org\/10.1002\/hon.2379","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,19]]}}}